← Leaderboards
James N Campbell
Centrexion Therapeutics Corporation
$8,662,635
Attributed
$8,662,635
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.5M · FY2021–24$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
Funding mix
By agency
NIH$8,662,635 · 2
By mechanism
UH3$6,612,268 · 1
UG3$2,050,367 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Acute Pain”
- Abraham Aizer Brody · New York University School Of Medicine$18,899,006
- Cecile Feldman · Rbhs-School Of Dental Medicine$11,278,781
- Bryan L McLaughlin · Micro-Leads, Inc.$9,612,607
- Jeffrey Reich · Sparian Biosciences, Inc.$8,261,211
- Joseph A Janicki · Lurie Children'S Hospital Of Chicago$5,541,590
- Navid Khodaparast · Spark Biomedical Inc$5,526,781
Research focus
Acute PainAdverse EffectsAgonistAddictionAmericanAnalgesicsAnalogAnalytical MethodBehavioralAlternative TreatmentBlindedBloodBlood - Brain Barrier AnatomyBolus InfusionBrainBypassCanis FamiliarisCathetersChronicChronic Low Back PainChronic PainBiologicalClinical DevelopmentCombat
Grant awards (3)
Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain$3,539,507
UH3 · FY2024 · NS · contact PI
Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain$3,072,761
UH3 · FY2023 · NS · contact PI
Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain$2,050,367
UG3 · FY2021 · NS · contact PI